- Home
- IMCC vs EVAX Comparison
IMCC vs EVAX Comparison
Compare IMCC & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMCC | EVAX |
|---|---|---|
| Founded | 1980 | 2008 |
| Country | Israel | Denmark |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1M | 31.9M |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | IMCC | EVAX |
|---|---|---|
| Price | $0.62 | $3.84 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $11.67 |
| AVG Volume (30 Days) | ★ 92.4K | 31.2K |
| Earning Date | 04-06-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $47.12 | N/A |
| Revenue Next Year | $12.83 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.54 | $1.20 |
| 52 Week High | $7.12 | $12.15 |
Technical Indicators
Market Signals| Indicator | IMCC | EVAX |
|---|---|---|
| Relative Strength Index (RSI) | 32.51 | 53.50 |
| Support Level | N/A | $2.45 |
| Resistance Level | $1.05 | $4.64 |
| Average True Range (ATR) | 0.09 | 0.37 |
| MACD | -0.00 | 0.08 |
| Stochastic Oscillator | 11.03 | 51.60 |
Price Performance
Historical ComparisonAbout IMCC IM Cannabis Corp.
IM Cannabis Corp is a Canada-based international medical cannabis company. It operates in the field of medical cannabis, through Focus Medical Herbs Ltd. (Focus), which holds a cultivation license to breed, grow, and supply medical cannabis products The majority of its revenues are generated from sales of medical cannabis products to customers in Israel. The remaining revenues are generated from sales of medical cannabis, as well as other products, to customers in Germany. Geographically, the majority is from Israel.
About EVAX Evaxion Biotech
Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.